Literature DB >> 31685482

A Comparative Analysis of Cytochrome P450 Activities in Paired Liver and Small Intestinal Samples from Patients with Obesity.

Veronica Krogstad1, Alexandra Peric2, Ida Robertsen2, Marianne K Kringen2, Christine Wegler2, Philip Carlo Angeles2, Jøran Hjelmesæth2, Cecilia Karlsson2, Shalini Andersson2, Per Artursson2, Anders Åsberg2, Tommy B Andersson2, Hege Christensen2.   

Abstract

The liver and small intestine restrict oral bioavailability of drugs and constitute the main sites of pharmacokinetic drug-drug interactions. Hence, detailed data on hepatic and intestinal activities of drug metabolizing enzymes is important for modeling drug disposition and optimizing pharmacotherapy in different patient populations. The aim of this study was to determine the activities of seven cytochrome P450 (P450) enzymes in paired liver and small intestinal samples from patients with obesity. Biopsies were obtained from 20 patients who underwent Roux-en-Y gastric bypass surgery following a 3-week low-energy diet. Individual hepatic and intestinal microsomes were prepared and specific probe substrates in combined incubations were used for determination of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A activities. The activities of CYP2C8, CYP2C9, CYP2D6, and CYP3A were quantified in both human liver microsomes (HLM) and human intestinal microsomes (HIM), while the activities of CYP1A2, CYP2B6, and CYP2C19 were only quantifiable in HLM. Considerable interindividual variability was present in both HLM (9- to 23-fold) and HIM (5- to 55-fold). The median metabolic HLM/HIM ratios varied from 1.5 for CYP3A to 252 for CYP2C8. The activities of CYP2C9 in paired HLM and HIM were positively correlated (r = 0.74, P < 0.001), while no interorgan correlations were found for activities of CYP2C8, CYP2D6, and CYP3A (P > 0.05). Small intestinal CYP3A activities were higher in females compared with males (P < 0.05). Hepatic CYP2B6 activity correlated negatively with body mass index (r = -0.72, P < 0.001). These data may be useful for further in vitro-in vivo predictions of drug disposition in patients with obesity. SIGNIFICANCE STATEMENT: Hepatic and intestinal drug metabolism is the key determinant of oral drug bioavailability. In this study, paired liver and jejunum samples were obtained from 20 patients with obesity undergoing gastric bypass surgery following a 3-week low-energy diet. We determined the hepatic and small intestinal activities of clinically important P450 enzymes and provide detailed enzyme kinetic data relevant for predicting in vivo disposition of P450 substrates in this patient population.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31685482     DOI: 10.1124/dmd.119.087940

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

1.  Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range.

Authors:  Kine Eide Kvitne; Kristine Hole; Veronica Krogstad; Birgit Malene Wollmann; Christine Wegler; Line K Johnson; Jens K Hertel; Per Artursson; Cecilia Karlsson; Shalini Andersson; Tommy B Andersson; Rune Sandbu; Jøran Hjelmesæth; Eva Skovlund; Hege Christensen; Rasmus Jansson-Löfmark; Anders Åsberg; Espen Molden; Ida Robertsen
Journal:  Eur J Clin Pharmacol       Date:  2022-06-01       Impact factor: 3.064

2.  Association between CYP2B6 c.516G >T variant and acute leukaemia: A protocol for systematic review and meta-analysis.

Authors:  Xuan Xiong; Dongke Yu; Qiaoyue Gao; Yuan Zhang; Qinan Yin; Xiaotao Chen; Hongtao Xiao; Rongsheng Tong
Journal:  Medicine (Baltimore)       Date:  2021-08-13       Impact factor: 1.817

Review 3.  The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies.

Authors:  Meysam Zarezadeh; Ahmad Saedisomeolia; Mahoor Shekarabi; Masoud Khorshidi; Mohammad Reza Emami; Daniel J Müller
Journal:  Eur J Nutr       Date:  2020-11-03       Impact factor: 5.614

4.  Influence of Proteome Profiles and Intracellular Drug Exposure on Differences in CYP Activity in Donor-Matched Human Liver Microsomes and Hepatocytes.

Authors:  Christine Wegler; Pär Matsson; Veronica Krogstad; Jozef Urdzik; Hege Christensen; Tommy B Andersson; Per Artursson
Journal:  Mol Pharm       Date:  2021-03-19       Impact factor: 4.939

5.  Short- and long-term effects of body weight loss following calorie restriction and gastric bypass on CYP3A-activity - a non-randomized three-armed controlled trial.

Authors:  Kine Eide Kvitne; Ida Robertsen; Eva Skovlund; Hege Christensen; Veronica Krogstad; Christine Wegler; Philip Carlo Angeles; Birgit Malene Wollmann; Kristine Hole; Line Kristin Johnson; Rune Sandbu; Per Artursson; Cecilia Karlsson; Shalini Andersson; Tommy B Andersson; Jøran Hjelmesaeth; Rasmus Jansson-Löfmark; Anders Åsberg
Journal:  Clin Transl Sci       Date:  2021-08-26       Impact factor: 4.689

Review 6.  Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease.

Authors:  Julie Massart; Karima Begriche; Anne Corlu; Bernard Fromenty
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

7.  Age- and Diet-Dependent Changes in Hepatic Lipidomic Profiles of Phospholipids in Male Mice: Age Acceleration in Cyp2b-Null Mice.

Authors:  Melissa M Heintz; Ramiya Kumar; Kristal M Maner-Smith; Eric A Ortlund; William S Baldwin
Journal:  J Lipids       Date:  2022-03-29

8.  Drug Metabolites Potently Inhibit Renal Organic Anion Transporters, OAT1 and OAT3.

Authors:  Ling Zou; Pär Matsson; Adrian Stecula; Huy X Ngo; Arik A Zur; Kathleen M Giacomini
Journal:  J Pharm Sci       Date:  2020-09-07       Impact factor: 3.784

9.  Proteomics-Informed Prediction of Rosuvastatin Plasma Profiles in Patients With a Wide Range of Body Weight.

Authors:  Christine Wegler; Luna Prieto Garcia; Signe Klinting; Ida Robertsen; Jacek R Wiśniewski; Jøran Hjelmesaeth; Anders Åsberg; Rasmus Jansson-Löfmark; Tommy B Andersson; Per Artursson
Journal:  Clin Pharmacol Ther       Date:  2020-10-18       Impact factor: 6.875

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.